Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 45Neoplasms 6Colorectal Neoplasms 5Neoplasm Metastasis 4Adenocarcinoma 3Resectable Pancreatic Cancer 2Rectal Neoplasms 2Pancreatic Cancer Metastatic 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Urachal cancer 1Stomach Neoplasms 1Pancreatic Ductal Adenocarcinoma (PDAC) 1Pancreatic Cancer Non-resectable 1Pancreatic Adenocarcinoma 1Neoplasms, Basal Cell 1Locally Advanced Unresectable or Metastatic Solid Tumors 1Locally Advanced Pancreatic Adenocarcinoma 1Localized Pancreatic Adenocarcinoma 1Gastrointestinal Neoplasms 1Gastroesophageal Adenocarcinoma 1Gastro-enteropancreatic neuroendocrine tumor 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Islet Cell 1Carcinoma 1Borderline Resectable Pancreatic Cancer 1

Interventions

Gemcitabine 3folfirinox 2Cisplatin 2paricalcitol 1nimotuzumab 1Taxes 1Granulocyte-Macrophage Colony-Stimulating Factor 1Colony-Stimulating Factors 1Chemotherapy, Adjuvant 1Chemoradiotherapy, Adjuvant 1Albumin-Bound Paclitaxel 1Adjuvants, Immunologic 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Resectable Pancreatic Cancer × folfirinox × Clear all
NCT04472910 2026-03-12

NeoPancOne

University Health Network, Toronto

Phase NA Active not recruiting
84 enrolled
Gastrointestinal

Resectable Pancreatic Cancer

NCT05529940 2024-11-27

NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)

Seoul National University Hospital

Phase 3 Recruiting
609 enrolled
Gastrointestinal

Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡